A running feed of noteworthy coverage from outside PeptideProtocolHQ — news, research writeups, and
press from outlets covering the peptide space. New pieces are added regularly — the automated posting
process below featured them first, and as each new article is featured the one before it moves into the
library archive, so this page keeps growing. This is a curated selection, not a comprehensive news feed, and
inclusion here isn't an endorsement of any specific claim — read the original source for full context.
Some links below are affiliate links to our vendor partner; we may earn a commission if you make a purchase.
Weight Loss
Novo Nordisk (via BioSpace) · 2026-10-20
A new post hoc analysis of the Phase 3 REDEFINE 1 trial, presented at The Menopause Society's 2026 Annual Meeting, looked specifically at how CagriSema, Novo Nordisk's investigational combination of the amylin analog cagrilintide with semaglutide, performed in women with obesity or overweight. Among more than 2,300 women in the trial, those on the combination lost an average of a quarter of their body weight over roughly 68 weeks, with meaningful reductions in waist circumference and the vast majority losing at least a tenth of their starting weight. The benefit held up across premenopausal, perimenopausal, and postmenopausal subgroups. Novo Nordisk notes the analysis is exploratory and hypothesis-generating, and that CagriSema remains unapproved while the FDA reviews it, with gastrointestinal side effects being the most common tolerability issue.
Weight Loss
BioSpace · 2026-10-19
Altimmune shared new Phase 2b IMPACT trial data on pemvidutide, an investigational peptide that balances glucagon and GLP-1 receptor activity, showing improvements in liver fat, liver enzymes, and non-invasive markers of fibrosis in people with metabolic dysfunction-associated steatohepatitis (MASH) compared with placebo. The company reported that gastrointestinal side effects were mild to moderate, with fewer participants stopping treatment due to adverse events than those on placebo despite no dose-titration period. Separately, early research in an animal model found that pemvidutide meaningfully reduced alcohol intake, a finding the company says supports moving the peptide into further study for alcohol use disorder and alcohol-associated liver disease.
Immune
NeurologyLive · 2026-10-16
UCB won FDA approval for a once-daily autoinjector version of ZILBRYSQ (zilucoplan), a macrocyclic peptide that blocks the complement protein C5 at the neuromuscular junction, giving adults with antibody-positive generalized myasthenia gravis a second way to self-administer the therapy alongside the original prefilled syringe. Supporting studies found the new device delivered a complete dose in nearly all uses and that most patients, caregivers, and clinicians could complete an injection successfully on their very first try without any training. The approval builds on zilucoplan's original 2023 clearance, which rested on a placebo-controlled trial showing meaningful improvement in a standard myasthenia gravis symptom scale. UCB expects the autoinjector to reach U.S. pharmacies in early 2027.
Immune
HCPLive · 2026-10-13
A long-term extension of the Phase 2b ANTHEM-UC trial, presented at the American College of Gastroenterology's 2026 annual meeting, found that most patients with moderate-to-severe ulcerative colitis who responded to the oral peptide icotrokinra kept that response, along with remission and signs of gut-lining healing, all the way out through 76 weeks of treatment. Nearly all patients in remission at that point were no longer relying on steroids to stay there, and the large majority of participants remained on treatment for the full extension period. Researchers reported that icotrokinra continued to be well tolerated, with safety patterns similar to or better than placebo and no new concerns identified. Icotrokinra, which already holds FDA approval for plaque psoriasis under the brand name Icotyde, is now advancing into a Phase 3 program specifically for ulcerative colitis.
Weight Loss
GlobeNewswire (Zealand Pharma A/S) · 2026-10-07
Zealand Pharma reported positive Phase 2b ZUPREME-2 results for petrelintide, a once-weekly amylin-receptor peptide, in a placebo-controlled study of adults with overweight or obesity and type 2 diabetes. Participants on the peptide lost meaningfully more body weight and saw greater improvement in blood sugar control than those on placebo, with gastrointestinal side effects and discontinuation rates similar to placebo. The company says the results reinforce earlier Phase 2 data and support the ongoing global Phase 3 ZUPREME program, though petrelintide remains investigational and has not yet been approved by regulators.
Pain Management
News-Medical.Net · 2026-10-06
Researchers at Boston Children's Hospital's FM Kirby Neurobiology Center designed a short lipidated peptide (SLiP) that disrupts the interaction between the pain-signaling sodium channel NaV1.8 and its anchoring protein ankyrin-G inside nociceptor neurons. In mouse models of chronic neuropathic pain, the peptide quieted overactive pain-sensing neurons and reduced pain-like behavior while leaving the animals' normal, protective pain response intact. Published in Cell Reports Medicine, the findings point to a new route for non-opioid pain relief that may succeed where earlier sodium-channel-blocking drugs have stalled in the clinic. The underlying peptide technology has been licensed to Mimetic Medicines, which is now developing longer-acting versions for further development.
Immune
Johnson & Johnson · 2026-10-02
Johnson & Johnson's Phase 3 ICONIC-TOTAL trial tracked adults and adolescents with moderate-to-severe plaque psoriasis affecting hard-to-treat areas such as the scalp, nails, genitals, and hands and feet. Two-year results presented at the EADV Congress found that icotrokinra, an oral peptide that blocks the IL-23 receptor, sustained clear or almost-clear skin in roughly seven in ten participants overall, with even higher clearance rates at several of the specialized body sites tracked. The safety profile remained consistent with earlier studies, with no new concerns reported through two years of follow-up. The results reinforce icotrokinra's standing as the first targeted oral peptide approved for plaque psoriasis, building on its initial 2026 regulatory clearance.
Healing
PR Newswire (Cerapedics Inc.) · 2026-10-01
The Centers for Medicare & Medicaid Services granted New Technology Add-On Payment status to Cerapedics' PearlMatrix, a bone graft built around a short collagen-derived peptide called P-15, covering a large share of the added hospital cost for qualifying inpatient cases starting this month. The designation follows a pivotal trial in which more than twice as many patients achieved solid spinal fusion at six months compared with a standard bone-graft approach alone, including many patients with risk factors like smoking or diabetes that typically slow healing. Company leadership says the reimbursement should make the technology easier for hospitals to adopt, extending its benefit to more spinal fusion patients.
Weight Loss
American Journal of Managed Care (AJMC) · 2026-10-01
Boehringer Ingelheim's investigational dual glucagon/GLP-1 receptor agonist survodutide achieved up to 13.1% average weight loss and substantial A1C improvements over placebo in the Phase 3 SYNCHRONIZE-2 trial, which enrolled adults with type 2 diabetes and excess weight. Close to 80% of treated participants lost at least 5% of their body weight, and nearly a third reached near-normal blood sugar levels, with the company also reporting improvements in waist circumference and insulin resistance markers. Gastrointestinal effects were the most common side effects, in line with other drugs in its class, and survodutide remains an investigational therapy pending further study and regulatory review.
Weight Loss
Eli Lilly and Company (Investor Relations) · 2026-09-30
Eli Lilly's investigational combination therapy EloraTZP, which pairs the amylin receptor agonist eloralintide with its dual GIP/GLP-1 drug tirzepatide, produced significantly greater weight loss and A1C improvement than tirzepatide alone in a Phase 2b trial of adults with obesity and type 2 diabetes. Presented at the EASD 2026 meeting, the 48-week study found the added amylin component boosted both outcomes, with gastrointestinal side effects described as mostly mild to moderate and concentrated during dose escalation. Lilly says the results support advancing the combination into further testing, though the therapy remains investigational and is not yet FDA-approved.
Hormone
WebMD · 2026-09-25
The FDA approved Onswik (insulin efsitora alfa), Eli Lilly's new once-weekly basal insulin for adults with type 2 diabetes, based on results from four large QWINT trials enrolling more than 3,400 participants. In head-to-head comparisons against existing daily insulin injections, the long-acting peptide hormone lowered blood sugar about as effectively, with a similar safety profile, while meaningfully cutting the number of yearly injections patients need. The clearance is Lilly's fourth approval for the drug worldwide, following earlier regulatory green lights in Europe, Japan, and Mexico, and the company expects US pharmacy availability in the coming months.
Weight Loss
GlobeNewswire (Zealand Pharma A/S) · 2026-09-22
Zealand Pharma announced the start of its global Phase 3 ZUPREME program for petrelintide, a once-weekly amylin-receptor peptide designed to promote weight loss by restoring the body's sensitivity to the satiety hormone leptin. The three-study program will enroll roughly 7,000 participants across groups with obesity alone, obesity with type 2 diabetes, and established cardiovascular disease, comparing petrelintide against placebo. The announcement builds on earlier Phase 2 results in which the peptide produced double-digit weight loss with a tolerability profile the company described as largely comparable to placebo.
Weight Loss
BioSpace / Novo Nordisk · 2026-09-21
Novo Nordisk reported new Phase 3 results for its investigational combination therapy CagriSema, which pairs the amylin analog cagrilintide with semaglutide. In the REIMAGINE 5 trial, adults with type 2 diabetes on the combination lost significantly more weight than those on tirzepatide, while achieving comparable blood sugar control. A second trial, REDEFINE 9, found substantial weight loss versus placebo in adults with obesity or overweight, along with improvements in blood pressure and cholesterol markers. Novo Nordisk describes the combination as well tolerated in both studies, with an FDA decision expected later this year.
Weight Loss
PR Newswire (Eli Lilly and Company) · 2026-09-15
Eli Lilly shared new Phase 3 TRIUMPH-2 data at the EASD 2026 meeting showing that adults with obesity or overweight who also have type 2 diabetes lost a substantial share of body weight and saw meaningful drops in A1C after 80 weeks on the triple hormone receptor agonist retatrutide. Unlike the earlier TRIUMPH-1 trial, which studied people with obesity alone, this cohort specifically included patients managing diabetes, a group in which weight loss on therapy is typically harder to achieve. Lilly says the compound met all of its primary and key secondary goals, though the company notes retatrutide remains investigational and is not yet FDA-approved.
Longevity
ScienceDaily / Nature (UC Berkeley) · 2026-09-11
A study published in Nature by researchers at UC Berkeley found that semaglutide extended median lifespan in aged mice and improved muscle strength, blood sugar regulation, and spatial memory compared to untreated controls. In a head-to-head comparison, the GLP-1 drug outperformed calorie restriction on several measures of healthy aging, including exploratory behavior and metabolic stability, hinting at biological pathways beyond appetite suppression. The NIH-funded team also observed reduced inflammation and better tissue repair in treated animals. Researchers caution that the findings are limited to mice and do not yet show that Ozempic or similar drugs extend human lifespan.
Weight Loss
EurekAlert! (BioLife) · 2026-09-10
BioLife announced it has been granted a U.S. patent for an effervescent, dissolvable tablet technology designed to deliver GLP-1 peptides like semaglutide by mouth rather than by injection. The formulation works by creating a protective buffer in the stomach that helps shield peptide molecules from digestive breakdown, an approach distinct from the coatings or absorption enhancers used in past oral-peptide attempts. Preclinical testing found that semaglutide administered this way was measurably absorbed into the bloodstream, an early signal that the format could work in practice. The patent's claims extend through 2042 and cover several other GLP-1 drugs beyond semaglutide, underscoring the broader push toward needle-free versions of these widely used therapies.
Cognitive
GlobeNewswire (Teitur Trophics) · 2026-09-10
Danish biotech Teitur Trophics reported that its first-in-class circular peptide TT-P34 was safe and well tolerated across all doses in a Phase 1 trial spanning 55 healthy volunteers and 12 early-stage Parkinson's patients, including when combined with standard levodopa therapy. The peptide successfully crossed the blood-brain barrier and achieved the central nervous system exposure researchers were targeting, while most Parkinson's patients showed coordinated shifts in cerebrospinal-fluid proteins consistent with its intended action on mitochondrial and lysosomal function in neurons. The company says the data support moving to a Phase 2 trial in 2027 to test whether the peptide can slow disease progression.
Cognitive
ScienceDaily / Acta Psychiatrica Scandinavica (Griffith University) · 2026-09-07
A nationwide Swedish cohort study of nearly 15,000 people with bipolar disorder found that those taking semaglutide had a 21% lower risk of psychiatric hospitalization compared with non-users, an association not seen with two other GLP-1 medications studied. Published in Acta Psychiatrica Scandinavica by researchers at Griffith University, the analysis points to possible links between the drug's effects on inflammation and brain signaling and mood stability. The authors frame the finding as an observational signal rather than proof of a psychiatric benefit, and call for randomized controlled trials to confirm whether semaglutide meaningfully affects mental health outcomes in bipolar disorder.
Hormone
American Journal of Managed Care (AJMC) · 2026-08-29
The FDA has approved rusfertide, sold as Mimrylo, a first-in-class hepcidin-mimetic peptide for erythrocytosis in adults with polycythemia vera. Developed by Protagonist Therapeutics and Takeda, the self-injected peptide mimics the body's natural iron-regulating hormone to help keep red blood cell levels steady, reducing patients' reliance on routine therapeutic phlebotomy. In the pivotal Phase 3 VERIFY trial, a clear majority of rusfertide-treated patients achieved hematocrit control without needing phlebotomy, compared to a minority on placebo, alongside improvements in fatigue and quality-of-life measures. The approval introduces the first new mechanism-based treatment option for this chronic blood disorder in years.
Weight Loss
GlobalGenes (RARE Daily) · 2026-08-11
The UK's Medicines and Healthcare products Regulatory Agency expanded its authorization of Rhythm Pharmaceuticals' Imcivree (setmelanotide) to cover acquired hypothalamic obesity, a rare weight-gain condition that can follow a brain tumor, its treatment, or related injury to the hypothalamus. The decision, which came with UK orphan drug status, drew on the Phase 3 TRANSCEND trial, in which patients on the melanocortin-4 receptor peptide lost substantially more body weight over a year than those on placebo and reported reduced hunger. The expansion follows setmelanotide's earlier U.S. approval for the same rare condition, adding another regulatory milestone for a peptide therapy already used for other genetic forms of severe obesity.
Cognitive
News-Medical.Net · 2026-08-10
Drawing on a secondary analysis of nearly 3,000 older adults from the SELECT trial, this article reports that semaglutide slowed the worsening of a blood-based protein signature associated with future dementia risk over two years of follow-up. Participants on the therapy showed a meaningfully lower likelihood of shifting into higher-risk biomarker categories compared with placebo. The piece is careful to note this is a biomarker signal rather than proof of reduced dementia diagnoses, calling for further research to confirm real-world cognitive outcomes.
Weight Loss
BioSpace (Eli Lilly and Company) · 2026-07-23
Eli Lilly released new Phase 3 TRIUMPH-3 results for its investigational triple hormone receptor agonist retatrutide, this time studied in adults with severe obesity and established cardiovascular disease rather than the general obesity population covered in the earlier TRIUMPH-1 trial. Participants on the two highest doses lost roughly a fifth of their body weight on average over 80 weeks, among the largest reductions reported yet in a late-stage obesity trial. The study also tracked major cardiovascular events as a secondary measure, though those early results were not yet statistically conclusive in either direction. Lilly says this is now the fifth positive Phase 3 readout for retatrutide and supports plans to pursue FDA approval, though the therapy remains investigational and not yet approved.
Longevity
UC San Diego Today · 2026-06-02
A new analysis published in Nature Communications found that weekly semaglutide injections slowed multiple markers of biological aging in a 32-week clinical trial of adults with HIV-associated abdominal fat gain. Using epigenetic clocks that track DNA methylation patterns, researchers measured a meaningfully slower pace of aging and reduced mortality-linked aging signals compared with a placebo group, with effects spanning markers tied to inflammation, metabolic health, and several organ systems. A related pilot study in a second journal reported similar slowing of aging markers, along with signs of telomere lengthening, in people treated for fatty liver disease. The researchers emphasize these results point to a possible aging-slowing effect rather than proof that the drug reverses aging, and say larger, longer trials are still needed.
Weight Loss
American Journal of Managed Care (AJMC) · 2026-05-21
Coverage of Eli Lilly's Phase 3 TRIUMPH-1 trial reports that the triple hormone receptor agonist retatrutide produced substantial average body weight reduction over roughly two years of treatment, with a large share of participants reaching normal or near-normal BMI ranges. All tested strengths met the trial's primary goals, and researchers also noted improvements in related cardiometabolic markers. The results are described as reinforcing and extending earlier, smaller studies of the compound.
Weight Loss
ScienceDaily / European Association for the Study of Obesity · 2026-05-19
Research presented at the ECO 2026 congress, drawing on nearly 90,000 patient records, found that people who lost 15% or more of their body weight on GLP-1 therapy saw substantially lower rates of osteoarthritis, chronic kidney disease, obstructive sleep apnea, and heart failure over the following years.
Weight Loss
Healthline · 2026-04-24
This article summarizes new research finding that patients on tirzepatide who underwent common heart procedures experienced markedly lower rates of death, heart failure, and major cardiac events compared with those not taking the medication. Experts quoted in the piece frame the findings as further evidence that GLP-1-based therapies offer cardiometabolic benefits beyond weight management alone. The piece notes that larger prospective studies are still needed to confirm the effect.
Weight Loss
VCU Health News · 2026-04-14
Reporting on findings from the SELECT cardiovascular outcomes trial, this piece describes how semaglutide meaningfully lowered the rate of major cardiovascular events and improved markers of fatty liver disease in adults with obesity. A VCU researcher involved in the analysis calls the liver-related findings a strong rationale for considering the therapy in patients with fibrosis risk. The coverage frames the results as a significant expansion of semaglutide's known health benefits beyond weight loss alone.
Longevity
ScienceDaily / Nature Aging (University of Oslo) · 2026-03-24
Reviewing early clinical work in Nature Aging, researchers from the University of Oslo describe NAD+ as a cellular “fuel regulator” central to energy production and DNA repair, with early trial data pointing to benefits for memory, movement, and metabolic health as the field moves toward larger studies.
Cosmetic & Skin
Dermatology Times · 2025-12-01
A dermatology trade-press Q&A covers new delivery technology aimed at helping copper peptides like GHK-Cu penetrate deeper into skin instead of sitting on the surface. The formulation discussed showed measurable gains in skin density within a week for most study participants, with improvements holding at the four-week mark.
Immune
International Journal of Molecular Sciences (MDPI) · 2025-11-27
A peer-reviewed review compiles research on Thymosin Alpha-1's role in counteracting age-related immune decline, describing how it appears to support T-cell development, encourage dendritic cell maturation, and help keep inflammatory signaling in check. The authors also summarize evidence for activity beyond the immune system, including antioxidant effects and support for cardiovascular and nervous system function. The review frames these properties as part of ongoing scientific interest in the peptide's use for immune support in older adults.
Healing
USU News (Uniformed Services University) · 2025-11-25
A research collaboration between the Uniformed Services University, the U.S. Army Institute for Surgical Research, and Tufts University examined a regenerative peptide called TSN6 paired with a skin-grafting technique for severe wounds. The study, later named an 'Editor's Choice' selection in the journal Bioengineering, found the peptide helped skin cells migrate and rebuild collagen more effectively when delivered through a hydrogel. Researchers see the approach as a way to stretch limited donor skin supply for burn and trauma patients.
Weight Loss
ScienceDaily / UC San Diego School of Medicine · 2025-11-12
A UC San Diego study published in Cancer Investigation found colon cancer patients taking GLP-1 medications had less than half the five-year mortality rate of non-users, with the association holding up after adjusting for age, BMI, and cancer severity. Researchers are now calling for clinical trials to confirm the mechanism.
Hormone
Communications Chemistry (Nature Portfolio) · 2025-11-05
A team reporting in Communications Chemistry engineered a set of novel oxytocin peptide analogues and identified one, radiolabeled as [18F]dOTK8[SFB], as the first oxytocin-like tracer shown to selectively accumulate in oxytocin-receptor-rich tissue in animal imaging studies. The compound retained strong binding potency comparable to established tracers while enabling non-invasive visualization of the receptor system. The authors say the breakthrough opens the door to future human imaging studies of oxytocin signaling in socioemotional health.
Healing
SynergenX Health (BusinessWire) · 2025-10-06
A multi-location hormone and wellness clinic network announced it is adding BPC-157 and a CJC-1295/Ipamorelin combination to its supervised treatment menu, describing peptide therapy as a natural extension of the hormone-optimization work the practice already does under licensed provider oversight.
Cosmetic & Skin
International Journal of Medical Sciences · 2025-10-01
A peer-reviewed review in the International Journal of Medical Sciences surveyed a family of skin-regenerating tripeptides, with copper-binding GHK-Cu and its derivatives as a central focus, alongside related peptides like KPV and GPE. The authors reported that GHK-based formulations were associated with improved fibroblast migration, enhanced collagen production, and antimicrobial activity relevant to tissue repair. They characterized tripeptides broadly as a promising, multifunctional class of ingredients for skin regeneration, while noting that further work on stability and delivery methods would help fully realize their clinical potential.
Immune
Frontiers in Cellular and Infection Microbiology · 2025-09-23
Researchers used imaging techniques to show that LL-37, a peptide the body naturally produces in response to vitamin D, physically surrounds the SARS-CoV-2 spike protein and interferes with its ability to latch onto the ACE2 receptor human cells use for viral entry. The peptide was also observed binding to two other viral proteins linked to immune evasion, suggesting a broader protective role. The authors describe the findings as supporting further investigation into LL-37's potential as part of the body's antiviral defenses.
Longevity
Biogerontology (Springer) · 2025-09-21
A study published in the journal Biogerontology found that the tetrapeptide epitalon lengthened telomeres in normal human fibroblasts and epithelial cells by boosting telomerase activity after several weeks of treatment. Notably, this telomerase-driven effect was distinct from the alternative lengthening mechanism seen only in cancer cell lines, leading the researchers to suggest epitalon may be safely explored in healthy cells. The authors note the work is an early-stage in vitro study and call for future validation in animal models.
Longevity
Experimental & Molecular Medicine (Nature Portfolio) · 2025-08-25
Researchers publishing in Experimental & Molecular Medicine report that the mitochondrial-derived peptide MOTS-c declines with age and that restoring it reduced senescence in pancreatic islet cells while improving glucose tolerance in aging and diabetic mouse models. The team also observed that people with type 2 diabetes have lower circulating MOTS-c levels than healthy individuals, reinforcing its link to metabolic aging. The authors propose MOTS-c as a candidate senotherapeutic worth further study for age-related metabolic decline.
Hormone
Endocrine Society (ENDO 2025 Press Release) · 2025-07-12
Researchers at Brigham and Women's Hospital, presenting at ENDO 2025, found that women with higher baseline oxytocin experienced less mood disturbance after fragmented sleep, suggesting the hormone may act as a protective buffer during hormonally sensitive periods like the postpartum stage and menopause transition. The study followed 38 healthy premenopausal women through controlled sleep-disruption protocols. The lead investigator described oxytocin as a potential biological safeguard worth further clinical exploration.
Immune
Frontiers in Immunology · 2025-06-17
Pooling five randomized controlled trials and 706 patients, this meta-analysis found that thymosin alpha-1 improved immune cell balance, lowered C-reactive protein, and reduced the rate of extrapancreatic infections in patients with severe acute pancreatitis — a notable result for a genuinely difficult-to-treat condition.
Longevity
ScienceDaily · 2025-05-07
An international research team found that raising levels of the longevity protein Klotho in aging mice lengthened lifespan and improved muscle, bone, and brain health, including signs of new neuron growth. The researchers have filed patents around the approach and describe it as a promising path toward therapies that address multiple hallmarks of aging at once. The findings add to a growing body of work positioning Klotho biology as a serious target for longevity science.
Growth Hormone
GlobeNewswire · 2025-03-25
The FDA cleared a new, more concentrated formulation of the growth-hormone-releasing factor analog tesamorelin, marketed as EGRIFTA WR, for treating excess visceral abdominal fat in people with HIV-associated lipodystrophy. The updated version requires reconstitution only once a week instead of daily and cuts the injection volume by more than half, a meaningful convenience improvement for long-term patients. Manufacturing also moved to a U.S.-based facility, and the product's patent protection was extended out to 2033, reflecting continued long-term investment in the therapy.
Hormone
The Journal of Clinical Endocrinology & Metabolism · 2025-02-26
A double-blind, placebo-controlled crossover trial of 95 participants found that kisspeptin-54 reliably stimulated reproductive hormone release as intended, while producing no measurable increase in anxiety across psychological, hormonal, or cardiovascular measures. The researchers describe the result as clinically reassuring, since earlier animal data had raised questions about kisspeptin's effect on mood and stress. The findings support continued development of kisspeptin-based approaches for reproductive and sexual health conditions.
Cosmetic & Skin
ScienceDaily (The Endocrine Society) · 2025-02-25
A review published in Endocrine Reviews and covered by the Endocrine Society examined how hormones and peptides, including alpha-melanocyte-stimulating hormone (alpha-MSH) and insulin-like growth factor 1, help govern the biological pathways behind skin wrinkling and hair graying. The authors described these pigment- and connective-tissue-regulating pathways as promising future targets for cosmetic and dermatologic intervention. The coverage highlighted this line of research as an encouraging, emerging direction for addressing visible skin and hair aging at a mechanistic level.
Cosmetic & Skin
Dermatology Times · 2024-08-22
An 84-day randomized, double-blind, placebo-controlled trial in women aged 40 to 65 found that daily oral collagen peptide supplementation measurably slowed visible signs of skin and nail aging compared to a placebo. Participants in the collagen group showed gains in skin density, elasticity, and hydration, along with a visible reduction in wrinkle depth over the study period. Nail appearance also benefited, with less yellowing observed in the collagen group than in the placebo group by the study's later timepoints.
Cognitive
Medical News Today · 2024-06-26
Medical News Today covers a study of the synthetic peptide PHDP5, which was delivered intranasally to mice with an Alzheimer's-like condition and was found to cross into the brain and lower harmful tau protein accumulation. Treated mice performed comparably to healthy animals on memory tasks, a notable improvement over untreated peers. A neurology specialist interviewed for the piece calls the results meaningful while cautioning that translation from mice to humans still needs further study.
Healing
EurekAlert! · 2024-02-14
Finnish researchers at Tampere University identified a short peptide, nicknamed CAR, that travels through the bloodstream and homes in on injured tissue to kick off the body's own repair signaling. In mouse experiments, wounds treated with the peptide closed faster and left smaller scars than untreated wounds. The team believes the same homing mechanism could eventually be adapted to support recovery from muscle tears and fractures, not just skin injuries.
Growth Hormone
Fierce Biotech · 2023-11-08
Lumos Pharma reported that its oral growth-hormone secretagogue receptor agonist LUM-201, closely related to ibutamoren (MK-677), met its primary and secondary goals in two Phase 2 trials for children with moderate growth hormone deficiency. Investigators found that treated children achieved height gains comparable to those seen with injectable growth hormone therapy, while the trial's safety profile was described as clean with no notable concerns identified. The company's leadership pointed to the data as validating a path toward a first-of-its-kind oral alternative to daily growth hormone injections.
Cognitive
MIT News · 2023-04-13
MIT News reports on a short synthetic peptide engineered to selectively block an overactive enzyme complex implicated in Alzheimer's-related brain damage, while sparing the enzyme's normal healthy form. In mouse models, the peptide crossed into the brain and reduced signs of neurodegeneration and inflammation, and treated animals performed better on spatial memory tasks. Outside experts quoted in the article describe the selectivity of the approach as unusually promising for future drug development.
Healing
PR Newswire (RegeneRx Biopharmaceuticals) · 2023-01-31
RegeneRx Biopharmaceuticals shared findings from an animal study showing that Thymosin Beta 4 encouraged new blood vessel growth and helped activate progenitor cells involved in tissue regeneration, effects observed even in tissue that wasn't previously injured. A researcher quoted in the release called the results encouraging while noting further study is needed to see whether the same activity holds up in aging or uninjured organs generally. The findings add to a body of animal research linking the peptide to recovery support across several organ systems.
Immune
Advances in Gerontology (Springer) · 2021-12-09
A clinical study published in the journal Advances in Gerontology compared older adults hospitalized with severe COVID-19 who received the thymus-derived peptide Thymalin alongside standard care to those who received standard care alone. The Thymalin group showed a notable rise in blood lymphocyte counts and a sharp drop in a key inflammation marker, along with lower hospital mortality than the comparison group. The researchers concluded the peptide appeared to help calm the excessive immune overreaction seen in severe COVID-19 while supporting the body's protective immune response.
Hormone
Palatin Technologies, Inc. · 2019-06-21
A genuine regulatory milestone for the peptide space: the FDA approved bremelanotide (PT-141) as Vyleesi, the first as-needed treatment for acquired, generalized hypoactive sexual desire disorder in premenopausal women — proof that a compound born as a research peptide can clear the full approval bar.
Growth Hormone
BioSpace · 2017-12-21
Macimorelin, an orally administered growth-hormone-secretagogue-receptor agonist marketed as Macrilen, received FDA approval as a diagnostic tool for adult growth hormone deficiency. The peptide-based agonist offered a simpler alternative to the previous diagnostic standard, which required intravenous insulin administration and multiple blood draws over an extended period. A clinical investigator quoted in the announcement described the new test as reliable, well tolerated, and considerably easier for patients than the older protocol.
Growth Hormone
BioSpace / Theratechnologies Inc. · 2008-06-18
The trial that helped pave the way to tesamorelin's eventual FDA approval: patients with HIV-associated lipodystrophy saw an 11% reduction in visceral fat versus baseline, with the loss concentrated specifically in visceral rather than subcutaneous fat — exactly the outcome the therapy was designed to produce.
No articles match your search. Try a different keyword or category.
